Narayana Hrudaya (NH)
Fast GrowerFairStock Score: 62/100 — STEADY
Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹1,832.6 |
| Market Cap | ₹37,220.08 Cr |
| P/E Ratio | 45.25 |
| ROCE | 20.75% |
| ROE | 21.48% |
| Dividend Yield | 0.25% |
| Profit Growth | 5.4% |
| Debt/Equity | 1.29 |
| Sales Growth | 80.4% |
| Free Cash Flow | ₹-339 Cr |
| Promoter Holding | 63.27% |
| 52-Week Range | ₹1,589 — ₹2,093.3 |
| Sector | Healthcare Services |
| Book Value | ₹223.4 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
I wear Graham's glasses and Buffett's patience, so I ask: what am I paying for? Narayana Hrudaya is a hospital business with real positives: ROE 21.48%, ROCE 20.75%, Piotroski 7/9, Altman Z 5.17, and promoters own 63.27%. Latest quarter sales of ₹2,151 Cr produced ₹127 Cr net profit. That suggests a viable, asset-heavy healthcare operator with some pricing and network advantages. But the numbers also show rough edges. Sales growth of 80.40% is striking, yet profit growth is only 5.40%—a wide gap that hints at cost pressure, depreciation, interest, or one-off revenue mix. The five-year revenue CAGR is 11.88%, respectable but not hyper-growth. Free cash flow is negative ₹339 Cr, and debt/equity is 1.29, so expansion is being funded partly by borrowings. Dividend yield is just 0.25%, so no meaningful cash return.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer